vs

Side-by-side financial comparison of DYNEX CAPITAL INC (DX) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

DYNEX CAPITAL INC is the larger business by last-quarter revenue ($43.5M vs $35.5M, roughly 1.2× RECURSION PHARMACEUTICALS, INC.). On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 531.3%). Over the past eight quarters, DYNEX CAPITAL INC's revenue compounded faster (75.8% CAGR vs 60.5%).

Dynex Capital Inc. is a publicly traded real estate investment trust headquartered in the United States. It specializes in investing in and managing a diversified portfolio of mortgage-backed securities, residential and commercial mortgage loans, and other mortgage-related assets. It delivers consistent returns to shareholders via regular dividends and long-term capital growth.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

DX vs RXRX — Head-to-Head

Bigger by revenue
DX
DX
1.2× larger
DX
$43.5M
$35.5M
RXRX
Growing faster (revenue YoY)
RXRX
RXRX
+150.4% gap
RXRX
681.7%
531.3%
DX
Faster 2-yr revenue CAGR
DX
DX
Annualised
DX
75.8%
60.5%
RXRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DX
DX
RXRX
RXRX
Revenue
$43.5M
$35.5M
Net Profit
$-108.1M
Gross Margin
59.8%
Operating Margin
-304.8%
Net Margin
-304.2%
Revenue YoY
531.3%
681.7%
Net Profit YoY
39.6%
EPS (diluted)
$1.59
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DX
DX
RXRX
RXRX
Q4 25
$43.5M
$35.5M
Q3 25
$30.6M
$5.2M
Q2 25
$23.1M
$19.2M
Q1 25
$17.1M
$14.7M
Q4 24
$4.5M
Q3 24
$26.1M
Q2 24
$14.4M
Q1 24
$-3.2M
$13.8M
Net Profit
DX
DX
RXRX
RXRX
Q4 25
$-108.1M
Q3 25
$150.4M
$-162.3M
Q2 25
$-13.6M
$-171.9M
Q1 25
$-3.1M
$-202.5M
Q4 24
$-178.9M
Q3 24
$-95.8M
Q2 24
$-97.5M
Q1 24
$40.1M
$-91.4M
Gross Margin
DX
DX
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
DX
DX
RXRX
RXRX
Q4 25
-304.8%
Q3 25
-3327.6%
Q2 25
-916.8%
Q1 25
-1297.9%
Q4 24
-4042.4%
Q3 24
-377.1%
Q2 24
-697.4%
Q1 24
-698.4%
Net Margin
DX
DX
RXRX
RXRX
Q4 25
-304.2%
Q3 25
491.3%
-3135.3%
Q2 25
-58.8%
-894.2%
Q1 25
-18.0%
-1373.3%
Q4 24
-3935.5%
Q3 24
-367.5%
Q2 24
-676.6%
Q1 24
-1256.8%
-662.4%
EPS (diluted)
DX
DX
RXRX
RXRX
Q4 25
$1.59
$-0.17
Q3 25
$1.08
$-0.36
Q2 25
$-0.14
$-0.41
Q1 25
$-0.06
$-0.50
Q4 24
$-0.56
Q3 24
$-0.34
Q2 24
$-0.40
Q1 24
$0.64
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DX
DX
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$531.0M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$2.5B
$1.1B
Total Assets
$17.3B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DX
DX
RXRX
RXRX
Q4 25
$531.0M
$743.3M
Q3 25
$491.0M
$659.8M
Q2 25
$387.5M
$525.1M
Q1 25
$327.4M
$500.5M
Q4 24
$594.4M
Q3 24
$427.6M
Q2 24
$474.3M
Q1 24
$295.7M
$296.3M
Total Debt
DX
DX
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
DX
DX
RXRX
RXRX
Q4 25
$2.5B
$1.1B
Q3 25
$2.0B
$1.0B
Q2 25
$1.6B
$919.1M
Q1 25
$1.4B
$933.9M
Q4 24
$1.0B
Q3 24
$524.6M
Q2 24
$584.4M
Q1 24
$958.5M
$401.2M
Total Assets
DX
DX
RXRX
RXRX
Q4 25
$17.3B
$1.5B
Q3 25
$14.2B
$1.4B
Q2 25
$11.3B
$1.3B
Q1 25
$9.0B
$1.3B
Q4 24
$1.4B
Q3 24
$726.5M
Q2 24
$775.9M
Q1 24
$6.3B
$557.8M
Debt / Equity
DX
DX
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DX
DX
RXRX
RXRX
Operating Cash FlowLast quarter
$120.8M
$-46.1M
Free Cash FlowOCF − Capex
$-47.3M
FCF MarginFCF / Revenue
-133.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DX
DX
RXRX
RXRX
Q4 25
$120.8M
$-46.1M
Q3 25
$68.3M
$-117.4M
Q2 25
$31.9M
$-76.4M
Q1 25
$6.4M
$-132.0M
Q4 24
$-115.4M
Q3 24
$-59.2M
Q2 24
$-82.2M
Q1 24
$-17.1M
$-102.3M
Free Cash Flow
DX
DX
RXRX
RXRX
Q4 25
$-47.3M
Q3 25
$-117.6M
Q2 25
$-79.6M
Q1 25
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-83.4M
Q1 24
$-109.0M
FCF Margin
DX
DX
RXRX
RXRX
Q4 25
-133.1%
Q3 25
-2272.5%
Q2 25
-413.9%
Q1 25
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-578.5%
Q1 24
-789.9%
Capex Intensity
DX
DX
RXRX
RXRX
Q4 25
3.5%
Q3 25
4.7%
Q2 25
16.4%
Q1 25
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
8.2%
Q1 24
48.2%
Cash Conversion
DX
DX
RXRX
RXRX
Q4 25
Q3 25
0.45×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
-0.43×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons